Last reviewed · How we verify
Product B
Product B is a marketed dermatological agent from Galderma R&D, but specific mechanistic details are not publicly available.
At a glance
| Generic name | Product B |
|---|---|
| Also known as | Salicylic acid |
| Sponsor | Galderma R&D |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Without access to the specific product identifier or additional clinical data, the precise mechanism of action cannot be reliably determined. Galderma R&D focuses on dermatology and aesthetic medicine, suggesting this product likely targets a skin condition, but confirmation of the exact molecular target and mechanism requires additional product information.
Approved indications
Common side effects
Key clinical trials
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (PHASE1, PHASE2)
- Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial (NA)
- Clinical Evaluation of an Experimental Remineralization Product (NA)
- Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Product B CI brief — competitive landscape report
- Product B updates RSS · CI watch RSS
- Galderma R&D portfolio CI